GenScript ProBio -- a mAb, Cell & Gene Therapy CDMO -- Raises $224 Million
publication date: Jan 18, 2023
GenScript ProBio of Nanjing, a biologics CDMO with operations around the globe, raised $224 million in a C round. ProBio offers end-to-end CDMO services from drug discovery to commercialization for antibodies, cell and gene therapies. The company said it would use the capital to increase manufacturing capacity, advance its R&D offerings and acquire companies that add services. After the funding, GenScript Biotech, a gene synthesis company, will continue to own 70% of ProBio, down from 80%, even though it added about $30 million to the funding. Legend Capital led the C round. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.